| Canonical pathways |
|
|
|
|
| Sirtuin signaling pathway |
.01 |
X |
|
11 |
| EIF2 signaling |
.006 |
|
X |
10 |
| Mitochondrial dysfunction |
.002 |
|
X |
9 |
| Oxidative phosphorylation |
.001 |
|
X |
8 |
| Hereditary breast cancer signaling |
.03 |
X |
|
6 |
| Oncostatin M signaling |
.003 |
|
X |
4 |
| Nucleotide excision repair pathway |
.003 |
|
X |
4 |
| Colanic acid building blocks biosynthesis |
.002 |
|
X |
3 |
| Methionine degradation I (to homocysteine) |
.005 |
|
X |
3 |
| Cysteine biosynthesis III (mammalia) |
.006 |
|
X |
3 |
| Glutathione-mediated detoxification |
.008 |
|
X |
3 |
| Superpathway of methionine degradation |
.02 |
X |
|
3 |
| Serine biosynthesis |
.003 |
|
X |
2 |
| Superpathway of serine and glycine biosynthesis I |
.006 |
|
X |
2 |
| γ-glutamyl cycle |
.02 |
X |
|
2 |
| UDP-N-acetyl-d-galactosamine biosynthesis I |
.02 |
X |
|
1 |
| Spliceosomal cycle |
.03 |
X |
|
1 |
|
l-DOPA degradation |
.03 |
X |
|
1 |
| GDP-l-fucose biosynthesis I (from GDP-D-mannose) |
.03 |
X |
|
1 |
| Top toxicological pathways |
|
|
|
|
| Mitochondrial dysfunction |
.003 |
|
X |
9 |
| Increased transmembrane potential of mitochondria and mitochondrial membrane |
.06 |
X |
|
3 |
| Decreased permeability transition of mitochondria and mitochondrial membrane |
.006 |
|
X |
2 |
| Glutathione depletion phase II reactions |
.04 |
X |
|
2 |
